

## IARC Monograph Meeting

### Participant conflict of interest statement

Please insert relevant text under the subheading below. The completed form should be signed and returned to: **TLO Policy News** c/o Dr Kurt Straif, **IARC Monograph Section, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon cedex 08, France. Fax: +33 (0)4 72 73 83 19. Email: imo@iarc.fr**

### Conflict(s) of interest

[Please declare any conflicts of interest here. If none exist, please state that there are none.]

Please indicate here which Monograph Meeting you have attended: \_\_\_\_\_

I agree with IARC's submission plan to send a synopsis of the Monograph meeting to *The Lancet Oncology* for publication, and the statement made above is, to the best of my knowledge, an accurate declaration. I understand that this statement may be published, either in part or in its entirety, in *The Lancet Oncology* at the discretion of the Editor. In addition, I will adhere to the press embargo and abstain from discussing in public any results from the Monograph meeting before the embargo has been lifted. The IARC Secretariat will inform all participants when the summary report is available online and when the embargo has been lifted.

Name (block capitals): \_\_\_\_\_

Affiliation and professional address (block capitals): \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Dear Monograph-Meeting participant,

A short synopsis of the key outcomes from the IARC Monograph meeting you have been invited to attend will be published in *The Lancet Oncology* prior to a full report in an upcoming *IARC Monograph*. In addition to compliance with IARC's policies on conflicts of interest, *The Lancet Oncology* also requires all meeting participants to provide a statement declaring competing interests.

*The Lancet Oncology* and IARC requires all participants to declare a Conflict of Interest if they, or their institution, has financial or personal relationships with other people or organisations that may inappropriately influence their actions. In particular, participants who, within the past 4 years and with a relevant company or competitor have stock, equity, a contract of employment, or a named position on a company board; or hold (or is applying for) a relevant patent (this restriction is for the life of the patent); or have (or will have) a fee from any organisation other than *The Lancet Oncology* or IARC must declare in writing the extent of the competing interest. Furthermore, *The Lancet Oncology* also requires participants to note receipt of any consultancies, honoraria, or speaker's fees; research funding or funding for equipment or supplies; travel or accommodation payments; or expert testimony fees from any organisation or source that could be an actual, or perceived, conflict of the interest.

Statements of declaration should be sent to Dr Kurt Straif. Dr Straif will provide copies of these statements to *The Lancet Oncology*'s editorial staff when the meeting synopsis is submitted for publication. Names of all participants will be published in *The Lancet Oncology* along with, at the journal's discretion, any conflicts of interest considered pertinent. Failure, or refusal, to provide a conflict of interest statement will be noted as such in the journal.

Thank you for your understanding.

Yours sincerely,

Dr David Collingridge

**Editor, *The Lancet Oncology***

32 Jamestown Road  
London NW1 7BY  
United Kingdom